Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target

• Published in: Oncotarget Vol. 6; no. 25; pp. 21421 - 21427
• Main Authors: Zeidan, Bashar, Jackson, Thomas R, Larkin, Samantha E T, Cutress, Ramsey I, Coulton, Gary R, Ashton-Key, Margaret, Murray, Nick, Packham, Graham, Gorgoulis, Vassilis, Garbis, Spiros D, Townsend, Paul A
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 28.08.2015
• Subjects: Aged; Annexin A3 - metabolism; Biomarkers, Tumor - metabolism; Breast - metabolism; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Line, Tumor; Cell Movement; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Epithelium - pathology; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Mass Spectrometry; MCF-7 Cells; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Proteomics; Research Paper; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; migration; breast cancer; Annexin A3; neoplasm; biomarker
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.4070

Breast cancers are the most common cancer-affecting women; critically the identification of novel biomarkers for improving early detection, stratification and differentiation from benign tumours is important for the reduction of morbidity and mortality.To identify and functionally characterise potential biomarkers, we used mass spectrometry (MS) to analyse serum samples representing control, benign breast disease (BBD) and invasive breast cancer (IDC) patients. Complementary and multidimensional proteomic approaches were used to identify and validate novel serum markers.Annexin A3 (ANX A3) was found to be differentially expressed amongst different breast pathologies. The diagnostic value of serum ANX A3 was subsequently validated by ELISA in an independent serum set representing the three groups. Here, ANX A3 was significantly upregulated in the benign disease group sera compared with other groups (P < 0.0005).In addition, paired breast tissue immunostaining confirmed that ANX A3 was abundantly expressed in benign and to a lesser extent malignant neoplastic epithelium. Finally, we illustrated ANX A3 expression in cell culture lysates and conditioned media from neoplastic breast cell lines, and its role in neoplastic breast cell migration in vitro.This study confirms the novel role of ANX A3 as a mammary biomarker, regulator and therapeutic target.